Using Value-Based RA Pathway Leads to a Shift to Biosimilars for AHG
Originally published in The Center for Biosimilars Biosimilars have struggled to gain ground in the United States, with few products launched, relatively low uptake of commercially available products, formulary restrictions that sometimes favor branded biologics over biosimilar options, and exclusionary contracting practices that block biosimilars from formularies altogether. A variety of policy proposals have been put forward to help […]
Using Value-Based RA Pathway Leads to a Shift to Biosimilars for AHG Read More »